Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...
Shranjeno v:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Artigo |
Jezik: | angleščina |
Izdano: |
2015
|
Online dostop: | https://doi.org/10.1111/cas.12814 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12814 |
Oznake: |
Označite
Brez oznak, prvi označite!
|